Marinus Pharmaceuticals, Inc. (MRNS)
Feb 11, 2025 - MRNS was delisted (reason: acquired by Immedica)
0.5500
+0.0010 (0.09%)
Inactive · Last trade price on Feb 11, 2025
Marinus Pharmaceuticals Employees
As of December 31, 2023, Marinus Pharmaceuticals had 166 total employees, including 165 full-time and 1 part-time employees. The number of employees increased by 13 or 8.50% compared to the previous year.
Employees
166
Change (1Y)
13
Growth (1Y)
8.50%
Revenue / Employee
$189,554
Profits / Employee
-$846,331
Market Cap
30.35M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 166 | 13 | 8.50% |
Dec 31, 2022 | 153 | 40 | 35.40% |
Dec 31, 2021 | 113 | 41 | 56.94% |
Dec 31, 2020 | 72 | 29 | 67.44% |
Dec 31, 2019 | 43 | 14 | 48.28% |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
MRNS News
- 7 months ago - MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNS - Business Wire
- 8 months ago - Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc. - Business Wire
- 9 months ago - Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results - Business Wire
- 10 months ago - Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives - Business Wire
- 10 months ago - Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting - Business Wire
- 10 months ago - 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity - Benzinga
- 10 months ago - Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens - Business Wire
- 11 months ago - Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting - Business Wire